• Exosome Diagnostics

  Participated · Series C · Jul 2017

  Exosome Diagnostics develops and commercializes exosome‑based, biofluid diagnostics using its ExoLution™ platform and point‑of‑care instrumentation ShahkyTM. Its flagship offering is the ExoDx® Prostate (IntelliScore) test, and the company is commercializing additional oncology diagnostic tests. Management plans to expand into other areas including neurodegenerative diseases, transplant rejection monitoring, and cardiology. Exosome Diagnostics is building out a companion diagnostics (CDx) business and expanding placement of exosomal instrumentation while advancing point‑of‑care clinical development. Technology differentiators cited include one‑reaction RNA and cell‑free DNA interrogation for signal enhancement and the ability to isolate disease‑specific exosomes by tissue type. The company completed a $30 million Series C financing to support rapid commercial expansion and further commercialization of its technologies. Exosome Diagnostics develops an exosome-based liquid biopsy platform that isolates and analyzes exosomal RNA, DNA and proteins from biofluids to enable non-invasive molecular diagnostics. The company’s tests analyze exoRNA for cancer biomarkers and its platform can simultaneously interrogate exoRNA and cell-free DNA to enhance detection of rare mutations. Exosome Diagnostics also highlights protein biomarker interrogation capabilities to broaden its diagnostic scope. The company plans to launch combined RNA-plus-DNA commercial liquid biopsy tests and pursue potential companion-diagnostic programs with pharma. It intends to expand development beyond oncology into areas such as neurodegenerative, inflammatory, metabolic, and cardiovascular diseases. Financially, Exosome Diagnostics completed a $60 million Series B financing to support growth of its commercial diagnostics, regulatory, and companion-diagnostics divisions and to advance new test and biomarker development. Exosome Diagnostics develops exosome-based molecular diagnostics that isolate and analyze exosomal RNA (exoRNA) and can also analyze cell-free DNA (cfDNA) from biofluids such as plasma, urine and saliva. Its liquid biopsy tests analyze exoRNA for cancer biomarkers and the platform is positioned to be applied to non-oncology indications as well. The company announced a $17.6M extension of its Series B, bringing the total Series B financing to $44.7M, and said the funds will support commercial and development efforts. Planned near-term commercial launches in 2015 include two blood-based lung cancer liquid biopsies (detecting ALK and T790M mutations), a urine-based prostate cancer liquid biopsy, and a 26-gene solid tumor panel offered initially as an LDT. It is developing a next-generation solid tumor panel planned for 2016 to detect 88 genes and thousands of mutations, and is beginning early development of diagnostics for neurodegenerative diseases. Management says the financing positions the company to transition to a commercial-stage company and expand its exosome-based tests across additional disease areas. Exosome Diagnostics develops fluid-based molecular diagnostic tests that analyze exosomes and other microvesicles in biofluids (blood, urine, cerebrospinal fluid) to detect disease-specific genetic material. Led by CEO James McCullough, the company positions its platform for personalized medicine and oncology applications. Planned near-term product launches include EXO106 (a prostate-cancer diagnostic to reduce unnecessary biopsies) and exoRNeasy research kits for RNA extraction targeted for Q2 2014. Under an expanded collaboration with QIAGEN the company is developing EXO501, a blood-based test to measure an actionable mutation in non-small cell lung cancer for non-invasive, repeated tumor mutation assessment. It is also developing EXO1000, a blood-based multi-gene clinically actionable biomarker panel for oncology. The company will use the new funding to support these product launches and continued R&D of its proprietary technology platform. Exosome Diagnostics develops exosome-based molecular diagnostics that detect cancer-specific genes from standard blood and urine samples. Its proprietary exosome technology enables minimally invasive testing for disease stratification and monitoring patient response to treatment. The company aims to further develop and commercialize a series of body-fluid-based oncology diagnostics using the new capital. Exosome Diagnostics is establishing R&D and service operations in New York and Munich to support development and commercialization. In conjunction with the financing it incorporated Exosome Diagnostics GmbH as a wholly owned subsidiary to serve as the European center for development and services. The company raised $20M in equity funding to advance these efforts.

• Cerapedics

  Participated · Series C · Dec 2012

  Cerapedics, led by CEO Glen A. Kashuba and based in Westminster, Colo., develops and commercializes a proprietary biomimetic small peptide (P-15) technology platform. Its core product, i-FACTOR Peptide Enhanced Bone Graft, is a biologic bone that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. The company received Premarket Approval (PMA) from the U.S. Food & Drug Administration for use of i-FACTOR in anterior cervical discectomy and fusion (ACDF) procedures. Cerapedics has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion (TLIF) surgery. The company intends to use new financing to accelerate commercialization and a U.S. lumbar trial for i-FACTOR. Cerapedics is a Westminster, CO-based orthobiologics company developing and commercializing bone graft substitute products for the treatment of orthopedic injuries. The company is focused on a proprietary synthetic small peptide (P-15) technology platform. Its flagship product, i-FACTOR Peptide Enhanced Bone Graft, incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. That mechanism is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. i-FACTOR is an FDA-approved product for Anterior Cervical Discectomy and Fusion (ACDF). The company is led by CEO Glen Kashuba and is pursuing broader commercialization and additional clinical study applications. Cerapedics develops and commercializes a proprietary synthetic small peptide (P-15) technology platform for orthopedic bone grafts. Its lead product, i-FACTOR Peptide Enhanced Bone Graft, incorporates a small peptide as an attachment factor to stimulate natural bone healing. i-FACTOR received FDA approval in November 2015 for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. The company plans to use new financing to expand commercialization of i-FACTOR and to further develop its P-15 technology for fusion in the lumbar spine. Cerapedics is led by CEO Glen Kashuba and is based in Westminster, Colorado. Recent financing activity reflects ongoing efforts to commercialize its technology and advance product development. Cerapedics develops and commercializes a proprietary synthetic small peptide (P-15) technology platform and the i-FACTOR biologic bone graft, which uses a small peptide as an attachment factor to stimulate bone healing. The company filed a Premarket Approval (PMA) application with the U.S. Food & Drug Administration for i-FACTOR in September 2014. Cerapedics plans to use recent financing to advance i-FACTOR's development and to expand commercialization in markets outside the U.S. The company is led by CEO Glen Kashuba and is based in Westminster, CO. Financially, the company has completed multiple financings, including the current raise and prior venture debt and equity rounds noted in company reports. Cerapedics is an orthobiologics company focused on developing and commercializing a proprietary synthetic small peptide (P-15) technology platform. Its lead product, the i-FACTOR bone graft, incorporates a small peptide as an attachment factor to stimulate the natural bone healing process and is described as the only biologic bone graft that uses a small peptide in this way. The company says the mechanism is designed to support safer and more predictable bone formation at a lower cost compared to commercially available bone growth factors. Cerapedics is using the recent financing to support general business operations and to advance its U.S. regulatory process. The company is privately held and is based in Westminster, Colorado. Glen Kashuba is cited as Cerapedics’ CEO in the announcement.

• Small Bone Innovations

  Participated · Series F · Dec 2010

  Small Bone Innovations (SBi) develops and commercializes implants and technologies for small bones and joints, with its flagship STAR total ankle replacement and an upper and lower limb product portfolio. The company was founded in 2004 by Viscogliosi Brothers and has facilities in New York, NY; Morrisville, PA; Péronnas, France; Donaueschingen, Germany; and Kuala Lumpur, Malaysia, and has sold products in 46 countries. Management reports positive sales and business performance this year, with continued revenue growth and substantial reductions in operating expenses. SBi plans a more aggressive buildup of its direct sales organization in the United States to drive further adoption of the STAR ankle. The company is using new financing to refinance existing indebtedness and provide working capital to accelerate sales across its portfolio. Small Bone Innovations focuses on devices and treatments for small-bone joint repair and trauma reconstruction across the hand, upper limb and lower extremity. Its product portfolio includes the STAR™ total ankle joint replacement system and a stable core upper limb arthroplasty and trauma reconstruction line. The company plans to use proceeds from the latest financing to continue driving growth of the STAR ankle system and support its existing product portfolio. SBi was founded in 2004 and previously raised $144m in Series D and Series C rounds in June 2009. The company operates facilities in New York, NY; Morrisville, PA; Bourg-en-Bresse, France; Donaueschingen, Germany; and Kuala Lumpur, Malaysia. The recent capital infusion is intended to support continued commercial and product growth in its targeted small-bone joint markets. Small Bone Innovations develops orthopedic technologies and treatments focused on small bones and joints, notably its S.T.A.R.® total ankle replacement system. The company plans a worldwide rollout of the S.T.A.R. system, using new capital to fund inventory and expand surgeon education and training. Management says proceeds will also support new and expanded product offerings for both upper and lower limb anatomies and related clinical studies. SBi operates facilities in New York, Morrisville (PA), Bourg-en-Bresse (France), Donaueschingen (Germany) and Kuala Lumpur (Malaysia). The company distributes its products and technologies in more than 50 countries. Anthony G. Viscogliosi is Chairman & CEO. Small Bone Innovations (SBi) develops technologies and treatments for small bones and joints, with products for upper and lower limb anatomies. The company plans to introduce new products and improved versions in 2010 and to develop and initiate several studies to support clinical understanding of its portfolio. SBi closed a $30M credit facility to accelerate business expansion and refinance existing indebtedness. The facility allowed the company to fully repay approximately $13M of its existing debt. In conjunction with the credit facility closing, Helmut D. Link and the investor group of Link America, Inc. made an equity investment in SBi. The company was founded in 2004 and operates facilities in New York, NY; Morrisville, PA; Bourg-en-Bresse, France; Donaueschingen, Germany; and Kuala Lumpur, Malaysia.

• TME Pharma

  Participated · Series D · Oct 2010

  TME Pharma is a clinical-stage biotechnology company focused on developing therapies that target the tumor microenvironment, with lead assets NOX-A12 and NOX-E36. NOX-A12 is being studied in the GLORIA Phase 1/2 trial in glioblastoma and is planned for the OPTIMUS Phase 2 program in pancreatic cancer; NOX-E36 is being evaluated for ophthalmic diseases. Under CEO Diede van den Ouden (joined June 2025) the company has implemented a strategic restructuring and shifted to an outsourcing model to lower operating costs. Financially, the company raised €1.7M in May 2025 and is now securing an additional €500,000 via a private bond issuance to improve runway. Proceeds are intended to support R&D, a newly announced treasury investment strategy, and potential acquisitions and partnerships. The company is also pursuing cash-generating non-core activities, leveraging tax loss carryforwards and has opened exposure to digital assets via a crypto brokerage account to build a more profitable corporate structure. TME Pharma (ALTME) is a biotech focused on NOX-A12, an agent being developed for brain cancer, including glioblastoma. The company will use new funding to advance the phase 1/2 GLORIA trial in newly diagnosed brain-cancer patients who cannot receive standard chemotherapy. Proceeds are also earmarked to finalize a formal advisory meeting with the FDA on next clinical and regulatory steps for NOX-A12. TME Pharma plans to file IND applications and requests for an accelerated regulatory pathway using the funds. The financing extends the company’s financial visibility from February 2024 to May 2024. The company is referenced with a Berlin location in the article. NOXXON Pharma is a Berlin-based biotechnology company developing a class of therapeutics called Spiegelmers, oligonucleotides composed of the L-stereoisomer of RNA. The company is advancing these Spiegelmer therapeutics as its core product area. In May 2010 it raised €33m as part of its Series D, and it has now completed an additional €2m, bringing the Series D aggregate to €35m. New investors in the most recent tranche include CD Ventures and other private partners. The Series D syndicate also comprises a range of existing investors that have participated in the round. NOXXON currently employs approximately 60 people. NOXXON Pharma is a Berlin, Germany-based company developing mirror-image oligonucleotide therapeutics generated with its proprietary Spiegelmer® technology. Its lead products are NOX-E36, NOX-A12 and NOX-H94, targeting diabetic complications, oncology and hematology. These Spiegelmer® compounds act as inhibitors of their respective molecular targets. The company plans ongoing clinical and pre-clinical development of these lead programs. To support that work, NOXXON completed a financing in 2010. The funds will be applied to advance the listed clinical and preclinical programs.

• Valtech Cardio

  Participated · Series B · Feb 2010

  Valtech Cardio develops minimally-invasive surgical and transcatheter mitral valve repair and replacement technologies intended to correct or significantly improve mitral valve function and reduce or eliminate mitral regurgitation (MR). The company’s products target MR, a serious heart disorder characterized by incomplete closure of the mitral valve. Valtech completed a $17.8M Series B financing to advance its programs. According to Founder and COO Amir Gross, the funding will be used to complete development and initial clinical evaluation of several products. The company is based in Or Yehuda, Israel, with a U.S. office in Waltham, Massachusetts. The article does not disclose prior rounds, revenues, or user metrics.

No current team members are available.